← All trials
NCT06883305
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2025
- Primary completion
- Mar 13, 2029
- Completion date
- Jun 5, 2029
- First posted
- Mar 19, 2025
- Last posted
- Nov 10, 2025
- Enrollment
- 990
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- University of ManchesterOfficial
- AmgenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.